Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study
- PMID: 20008472
- PMCID: PMC3498950
- DOI: 10.1093/rheumatology/kep361
Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study
Abstract
Objective: To develop and assess the psychometric properties of the Localized Scleroderma (LS) Skin Damage Index (LoSDI) and Physician Global Assessment of disease Damage (PGA-D).
Methods: Damage was defined as irreversible/persistent changes (>6 months) due to previous active disease/complications of therapy. Eight rheumatologists assessed the importance of 17 variables in formulating the PGA-D/LoSDI. LS patients were evaluated by two rheumatologists using both tools to assess their psychometric properties. LoSDI was calculated by summing three scores for cutaneous features of damage [dermal atrophy (DAT), subcutaneous atrophy (SAT) and dyspigmentation (DP)] measured at 18 anatomic sites. Patient GA of disease severity (PtGA-S), Children's Dermatology Life Quality Index (CDLQI) and PGA-D were recorded at the time of each examination.
Results: Thirty LS patients (112 lesions) and nine patient-visit pairs (18 lesions) were included for inter- and intra-rater reliability study. LoSDI and its domains DAT, SAT, DP and PGA-D demonstrated excellent inter- and intra-rater reliability (reliability coefficients 0.86-0.99 and 0.74-0.96, respectively). LoSDI correlated moderately with PGA-D and poorly with PtGA-S and CDLQI. PGA-D correlated moderately with PtGA-S, but poorly with CDLQI.
Conclusions: To complete the LS Cutaneous Assessment Tool (LoSCAT), we developed and evaluated the psychometric properties of the LoSDI and PGA-D in addition to the LS Skin Severity Index (LoSSI). These instruments will facilitate evaluation of LS patients for individual patient management and clinical trials. LoSDI and PGA-D demonstrated excellent reliability and high validity. LoSCAT provides an improved understanding of LS natural history. Further study in a larger group of patients is needed to confirm these preliminary findings.
Figures




Similar articles
-
The Localized Scleroderma Cutaneous Assessment Tool: responsiveness to change in a pediatric clinical population.J Am Acad Dermatol. 2013 Aug;69(2):214-20. doi: 10.1016/j.jaad.2013.02.007. Epub 2013 Apr 4. J Am Acad Dermatol. 2013. PMID: 23562760 Free PMC article.
-
The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures.J Rheumatol. 2009 Dec;36(12):2819-29. doi: 10.3899/jrheum.081284. Epub 2009 Oct 15. J Rheumatol. 2009. PMID: 19833758 Free PMC article.
-
Reliability of LoSCAT score for activity and tissue damage assessment in a large cohort of patients with Juvenile Localized Scleroderma.Pediatr Rheumatol Online J. 2018 Jun 18;16(1):37. doi: 10.1186/s12969-018-0254-9. Pediatr Rheumatol Online J. 2018. PMID: 29914516 Free PMC article.
-
Psychometric Properties of Patient Global Assessment in Psoriatic Arthritis: A Systematic Literature Review.J Rheumatol. 2024 Jun 1;51(6):603-612. doi: 10.3899/jrheum.2023-0722. J Rheumatol. 2024. PMID: 38359935
-
Disease course and long-term outcome of juvenile localized scleroderma: Experience from a single pediatric rheumatology Centre and literature review.Autoimmun Rev. 2018 Jul;17(7):727-734. doi: 10.1016/j.autrev.2018.02.004. Epub 2018 May 3. Autoimmun Rev. 2018. PMID: 29729451 Review.
Cited by
-
The correlation between serum E-selectin levels and soluble interleukin-2 receptors with relation to disease activity in localized scleroderma.Postepy Dermatol Alergol. 2018 Dec;35(6):614-619. doi: 10.5114/ada.2018.77613. Epub 2018 Nov 13. Postepy Dermatol Alergol. 2018. PMID: 30618531 Free PMC article.
-
Lichen Planus Activity and Damage Index (LiPADI)-Creation of the Questionnaire.J Clin Med. 2021 Dec 22;11(1):23. doi: 10.3390/jcm11010023. J Clin Med. 2021. PMID: 35011764 Free PMC article.
-
Associations between Disease Activity/Severity and Damage and Health-Related Quality of Life in Adult Patients with Localized Scleroderma-A Comparison of LoSCAT and Visual Analogue Scales.J Clin Med. 2020 Mar 11;9(3):756. doi: 10.3390/jcm9030756. J Clin Med. 2020. PMID: 32168819 Free PMC article.
-
Association between quality of life and clinical characteristics in patients with morphea.Qual Life Res. 2018 Oct;27(10):2525-2532. doi: 10.1007/s11136-018-1897-1. Epub 2018 Jun 19. Qual Life Res. 2018. PMID: 29922914
-
Health-related quality of life in morphoea.Br J Dermatol. 2015;172(5):1329-37. doi: 10.1111/bjd.13572. Epub 2015 Apr 8. Br J Dermatol. 2015. PMID: 25483169 Free PMC article.
References
-
- Torres JE, Sanchez JL. Histopathologic differentiation between localized and systemic scleroderma. Am J Dermatopathol. 1998;20:242–5. - PubMed
-
- Peterson LS, Nelson AM, Su WP, Mason T, O’Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol. 1997;24:73–80. - PubMed
-
- Arkachaisri T, Pino S. Localized scleroderma severity index and global assessments: a pilot study of outcome instruments. J Rheumatol. 2008;35:650–7. - PubMed
-
- Marzano AV, Menni S, Parodi A, et al. Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol. 2003;13:171–6. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials